Antibacterial Agents TRIZ Cases

New oral and injectable 9-aminomethyl tetracycline formulations improve bioavailability and stability to treat resistant bacterial infections.

Non-pyruvylated and partially pyruvylated Klebsiella O-antigen conjugates broaden subserotype coverage, including resistant strains.

Dual-target antibodies bind PcrV and Psl to reduce Pseudomonas load, inhibit biofilms, and stabilize lung function in bronchiectasis.

Specific E. coli strains establish gut colonization resistance to displace MDR Enterobacteriaceae without driving antibiotic resistance.

Modified pentamidine analogs target bacterial LPS to disrupt the Gram-negative outer membrane, boost antibiotic activity, and reduce toxicity.

Fear-inducing heterocyclic and isothiocyanate compounds activate TRPA1 to trigger hypothermia and anti-inflammatory protection.

By targeting the conserved ECF-ATP interface, these inhibitors block multiple vitamin uptake pathways and suppress resistant Gram-positive bacteria.

Fusion peptides raise MYC activity in target immune cells to boost leukocyte viability and immune response while limiting systemic side effects.

PorA epitope loops are inserted into an fHbp scaffold to preserve native conformation and broaden meningococcal vaccine coverage.

Structural changes to β-lactam side groups improve Gram-negative antibacterial activity while limiting drug resistance.

Thiol-reactive ADC linkers improve conjugation control, keep payloads stable in circulation, and release cytotoxic drugs more selectively in target cells.

A whey protein bio-complex adheres to oral surfaces and selectively kills pathogenic bacteria while preserving commensal flora in animals.

New triazoloquinazolinone derivatives inhibit S. aureus AgrA virulence signaling while retaining activity in human serum and albumin.

Near-infrared activated indocyanine green kills Gram-negative bacteria and mycoplasma without antibiotics, helping avoid drug resistance.

Protease- and pH-stable sdAbs bind C. difficile toxin B in the gut to block cytotoxicity, reduce recurrence, and preserve microbiome health.

Orthosomycin compounds delivered through the teat canal treat resistant mastitis pathogens in milk while limiting systemic absorption.

Filtered Croton lechleri latex targets MRSA, P. aeruginosa, and other skin pathogens while supporting healing and reducing inflammation.

A 12-epi pleuromutilin scaffold overcomes weak antiviral efficacy by blocking RNA virus entry and replication, including coronaviruses.

Small-molecule fascin inhibitors block tumor cell migration and invasion, adding a metastasis-focused treatment path beyond primary tumor growth control.

A C-9 modified minocycline composition treats or prevents resistant biodefense bacterial infections, including post-exposure use.

Selective control of STAT1 threonine 749 phosphorylation helps treat sepsis, colitis, and lupus without broadly blocking antiviral signaling.

Multi-coating oral capsules release oxygen in the intestinal lumen to suppress anaerobic bacteria without hyperbaric equipment.

Targeting the secreted LasB virulence factor weakens P. aeruginosa infections while avoiding membrane-penetration limits and reducing resistance pressure.

A modified monocyclic β-lactam compound targets resistant Gram-negative bacteria, including Pseudomonas aeruginosa, in pneumonia treatment.

A tryptophol acetate and tyrosol acetate composition disrupts quorum sensing to curb biofilms without driving antibiotic resistance.

Controlled light exposure and buffered formulation keep phthalocyanine dye conjugates stable, potent, and ready for targeted photoimmunotherapy.

A defined crystal form A improves stability and pharmacokinetic behavior of an FXR-modulating tricyclic compound for pharmaceutical use.

Heat-inactivated Mycobacterium bovis is used to induce broad protection against protozoan and bacterial infections while avoiding active mycobacterial harm.

Novel anti-TIM-3 antibodies use targeted hinge and glycosylation changes to improve binding affinity and neutralize TIM-3 activity.

Short HD-5 and HNP-4 peptide fragments target resistant pathogens while preserving gut microbiome balance and simplifying manufacture.

Using Leuconostoc and Lactobacillus in kimchi, this case shows food-based H. pylori inhibition without antibiotic resistance or gut flora disruption.

D-configured antimicrobial peptides improve stability and efficacy against MDR and XDR pathogens while reducing hemolytic activity.

Engineered HMGB1 derivatives sequester DNABII proteins to break biofilms, restore antimicrobial susceptibility, and avoid excess inflammation.

Histidine-based unnatural amino acids help peptides resist proteolysis, improve bacterial selectivity, and inhibit multi-resistant bacteria.

Cationic naphthoic acid polymers disrupt bacterial membranes to target MDR gram-negative bacteria while maintaining selectivity.

Quadruple-action topical compounds inhibit melanin, suppress acne bacteria, and reduce inflammation to treat acne vulgaris and PIH.

A hydrochloric acid-DMSO-water formulation improves porphyrin photosensitizer solubility while reducing toxicity and preserving carrier compatibility.